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High mortality rates have been reported for patients 
co-infected with extensively drug-resistant tuberculosis 
(XDR-TB) and HIV, but treatment outcomes have not been 
reported. We report treatment outcomes for adult XDR TB 
patients in KwaZulu-Natal Province, South Africa. Initial data 
were obtained retrospectively, and outcomes were obtained 
prospectively during 24 months of treatment. A total of 114 
XDR TB patients were treated (median 6 drugs, range 3–9 
drugs); 82 (73%) were HIV positive and 50 (61%) were 
receiving antiretroviral therapy. After receiving treatment 
for 24 months, 48 (42%) of 114 patients died, 25 (22%) 
were cured or successfully completed treatment, 19 (17%) 
withdrew from the study, and 22 (19%) showed treatment 
failure. A higher number of deaths occurred among HIV-
positive patients not receiving antiretroviral therapy and 
among patients who did not show sputum culture conversion. 
Culture conversion was a major predictor of survival but was 
poorly predictive (51%) of successful treatment outcome.
Drug-resistant tuberculosis (TB) is a critical threat to TB control and global public health (1–3). Nowhere 
is this threat more pressing than in South Africa, where 
drug-resistant TB and HIV have converged in a deadly 
syndemic defined by increased incidences of TB and HIV 
(4), endemic transmission of drug-resistant TB strains (5), 
high mortality rates (6), and poor treatment outcomes (7). 
The most drug-resistant form of TB, extensively drug-
resistant tuberculosis (XDR TB) (8) has been reported in 70 
countries and comprises an increasing proportion of drug-
resistant TB cases (1).
The global epicenter of the XDR TB and HIV syndemic 
is KwaZulu-Natal Province in South Africa, where nearly 
400 XDR TB patients, 70% co-infected with HIV, were 
admitted to a provincial TB referral hospital for initiation 
of therapy during 2003–2008 (9). To contextualize this 
incidence, 73% (573/782) of all XDR TB cases reported 
to the World Health Organization globally during 2002–
2009 were from South Africa (3,10). It is estimated that 
50% of patients with a diagnosis of XDR TB in KwaZulu-
Natal Province do not survive to treatment referral (11). 
Therefore, hospital-based surveillance represents a major 
underestimate of cases of co-infection with XDR TB and 
HIV in the province.
Without adequate second-line TB and HIV treatment, 
reported mortality rates for persons co-infected with XDR 
TB and HIV approach 100% (6). Among XDR TB patients 
who survive to initiation of second-line TB therapy, early 
treatment outcomes reported by our group and others 
describe low rates of sputum culture conversion, major 
adverse events, and a substantial number of early deaths 
(12–14). To our knowledge there are no published reports 
of outcomes for patients co-infected with XDR TB and HIV 
at the end of TB treatment. This report describes treatment 
outcomes, adverse events, and risk factors for death among 
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in the first 60 patients in this cohort have been reported 
(12). In brief, patients were adult (>18 years of age) XDR 
TB patients consecutively admitted to a public TB referral 
hospital in KwaZulu-Natal Province in South Africa 
during December 1, 2006–October 31, 2007 for initiation 
of treatment for XDR TB. Patients with complications and 
drug-resistant TB are referred to this facility at the discretion 
of the treating physician and are admitted depending on 
patient acuity and bed availability. The practice during 
the study period was to admit all XDR TB patients for 
initiation of second-line TB treatment. Eligible participants 
had culture-proven TB and Mycobacterium tuberculosis 
infection, and drug susceptibility testing results meeting 
the revised World Health Organization criteria for XDR 
TB (10). In addition, patients agreed to begin appropriate 
second-line and third-line anti-TB treatment. All anti-TB 
treatment regimens were determined by treating physicians 
on the basis of drug susceptibility results and adverse drug 
reactions. All treatment was provided through the South 
African public health system and directly observed therapy 
was provided. However, we did not assess the quality of 
directly observed therapy support or adherence.
Study Design
Patients who met eligibility criteria were identified 
retrospectively, and information was collected by chart 
review and review of an electronic laboratory database. 
Information on demographics, risk factors and adverse 
drug reactions, and treatment outcomes were collected 
retrospectively. Treatment outcomes of enrolled patients 
were followed through December 31, 2009, to ensure 
that each patient had >24-months of follow-up. Standard 
drug-resistant TB treatment outcome definitions were used 
to define outcome (15). Treatment outcomes were cure, 
treatment completion, death, and treatment default (15).
All drug-resistant TB treatment outcomes were 
mutually exclusive and were defined at <24 months except 
in the case of treatment default and death, which were 
defined when they occurred. Cure was defined as treatment 
for 24 months and >5 consecutive negative culture results 
in the final 12 months of treatment. Treatment completion 
was defined as treatment for 24 months, with clinical 
improvement, and negative cultures after treatment, but 
did not meet the definition for cure because of lack of 
bacteriologic results (<5 cultures performed in the final 12 
months of therapy). If 1 culture was positive for TB but 
there was no clinical deterioration, the patient was still 
considered cured or that treatment was completed provided 
that this result was followed by >3 monthly negative 
cultures. Treatment failure was defined as treatment for 24 
months with clinical improvement and negative cultures 
after treatment, but did not meet the but >2 of 5 cultures 
in the final 12 months were positive, or if any 1 of the final 
3 cultures was positive for TB, or if clinical failure was 
indicated by the clinician. Default was defined as treatment 
interrupted for >2 consecutive months for any reason. 
Death was defined as death of a patient for any reason 
during treatment.
TB sputum culture conversion was defined as 
having >2 negative consecutive sputum cultures 30 days 
apart after initiation of treatment. Patients may have 
subsequently showed reversion to a status of TB sputum 
culture positive. Adverse events were recorded by clinical 
staff. Severe adverse events were defined as events causing 
new hospitalization, stopping a drug in the regimen, 
urgent/emergent treatment, or death (16). In addition, 
electrolyte abnormalities (potassium level <2.5 mmol/L or 
magnesium level <1.5 mmol/L) attributed to medication 
use, were considered to be severe adverse events. The 
study protocol was approved by the Biomedical Research 
Ethics Committee of the University of KwaZulu-Natal 
and the Institutional Review Board of Boston University 
Medical Center.
Drug Susceptibility Testing
Drug susceptibility testing for first-line and second-
line drugs was performed at the provincial TB referral 
laboratory in Durban, South Africa. Culture positivity was 
determined by using the BACTEC MGIT 960 fluorometric 
system (Becton Dickinson Diagnostics, Sparks, MD, 
USA). Drug susceptibility testing for isoniazid, rifampin, 
ethambutol, streptomycin, ethionamide, ofloxacin, 
and kanamycin was performed by using the modified 
proportional growth method on 7H11 agar according to 
standard techniques (17,18). Drug susceptibility testing 
for capreomycin, p-aminosalacylic acid (PAS), terizidone, 
cycloserine, and pyrazinamide was not available during the 
study period because of technical and resource availability 
issues. Sputum samples for culture were routinely obtained 
on a monthly basis.
Statistical Analysis
All participants in the study were included in an 
analysis of risk factors for survival and unfavorable 
treatment outcome. For the survival analysis, we included 
all patients who died, even if they defaulted before death, 
as deaths. For the unfavorable treatment outcome analysis, 
unfavorable treatment outcome included death, treatment 
failure, and default. Successful treatment outcome included 
cure and treatment completion. Cox proportional hazards 
models were used to estimate hazard ratios (HRs) and 
95% CIs. Significant variables or variables that caused 
>10% change in the bivariate HR were included in the 
multivariate model. We calculated 95% CIs by using 
a normal approximation of the binomial distribution. 
The Fischer exact test or χ2 test was used to compare 
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categorical variables. Medians were compared by using the 
Wilcoxon Mann-Whitney U test. Kaplan-Meier survival 
curves for death and for time to culture conversion were 
calculated from time of XDR TB treatment initiation with 
appropriate anti-TB drugs. Participants were censored at 
time of default or death. The p values for survival analysis 
were determined by using Cox proportional hazards model 
adjusted for potential confounding variables, as per above. 
Analysis was performed by using SAS version 9.2 software 
(SAS Institute, Cary, NC, USA).
Results
During 2006–2007, a total of 6,127 persons in KwaZulu-
Natal Province were given a diagnosis of multidrug-
resistant TB (MDR TB) (5,612) or XDR TB (536) (19). Of 
those 6,127 persons, 2,013 (1,771 with MDR-TB and 242 
with XDR TB) were admitted to King George V Hospital 
for initiation of treatment during the 2-year study period 
(December 2006–October 2007). During this period, 130 
consecutive patients with XDR TB were admitted to King 
George V Hospital for initiation of treatment. Four of these 
patients refused treatment, 2 patients had insufficient data, 
6 patients died before the start of treatment, and 4 patients 
were <18 years of age. The remaining 114 XDR TB patients 
were eligible and were analyzed during the study.
The patients included in this study were transferred 
from 41 distinct municipalities or areas representing 9 
(82%) of 11 health districts in KwaZulu-Natal Province. 
The most common addresses patients reported were in the 
Tugela Ferry catchment area (31%), metropolitan Durban 
(14%), and Pietermaritzburg (11%). Most (57%) patients 
were female patients, young (median age 35 years), and 
co-infected with HIV (77% with a known test result) (Table 
1). Female patients were significantly younger (median 
age 31 years vs. 39 years; p<0.001) and more likely to be 
co-infected with HIV (80% vs. 61%; p = 0.01) than male 
XDR TB patients. Most (81%) patients had been treated 
previously for TB; fewer (37%) had been previously 
treated for MDR-TB. Fifty (61%) of 82 patients with 
known HIV infection were receiving antiretroviral therapy 
(ART) before hospital admission or initiated ART therapy 
early during treatment for XDR TB with efavirenz-based 
regimens. A total of 42 (37%) patients showed TB sputum 
culture conversion during treatment. Eighteen (43%) of 
42 patients who showed culture conversion subsequently 
showed culture reversion (n = 7), defaulted (n = 7), or died 
(n = 4).
Patients were treated with a median of 6 drugs 
(interquartile range [IQR] 5–7 drugs). The most 
common initial regimens included capreomycin (90%), 
PAS (90%), pyrazinamide (92%), ethionamide (92%), 
ethambutol (97%), cycloserine (66%), or terizidone (30%). 
Moxifloxacin (1%) and leveofloxacin (0%) were not 
available through the public health care system during the 
study period.
Adverse events during treatment occurred in 58% 
of patients; severe adverse events occurred in 25% of 
patients and were not associated with HIV status, ART, or 
treatment default. Within the HIV co-infected subgroup, 
there was an association between adverse events and 
death, this association was not significant by multivariate 
analysis. Physicians infrequently recorded a specific drug 
associated with the adverse event (29%): cycloserine 
(12%), capreomycin (8%), and PAS (4%) were the most 
common drugs related to adverse events. There were 
8 episodes of psychosis or severe psychiatric illness 
attributed to cycloserine, which resulted incessation of 
the use of this drug. There were 4 deaths in the cohort 
attributed to hypokalemia or hypomagnesemia related 
to use of capremoycin. These events decreased over the 
study period as physicians empirically supplemented 
potassium and magnesium for patients during treatment 
with capreomycin.
Treatment outcomes were determined 24 months after 
the initiation of treatment (Table 2). All treatment outcome 
categories were mutually exclusive. By 24 months, 48 (42%) 
of 114 patients had died, 25 (22%) of 114 were either cured 
or completed treatment, 19 (17%) of 114 defaulted, and 22 
(19%) of 114 showed treatment failure (Table 2). Kaplan-
Meier survival and culture conversion curves from start of 
XDR TB therapy are shown in Figures 1 and 2. Deaths of 
patients after they defaulted (n = 1) were counted as deaths 
in survival analysis. HIV status was not associated with a 
higher mortality rate or culture conversion, but among HIV-
infected XDR TB patients, receiving ART was associated 
with improved survival but not improved sputum culture 
conversion. Patients who showed culture conversion early 
or late during treatment had improved survival by Kaplan-
Meier analysis (Figure 2, panel B).
TB culture conversion at 2 months of treatment was 
associated with survival by bivariate analysis (HR 5.55, 95% 
CI 1.75–20.0) and multivariate analysis (HR 5.0, 95% CI 
1.49–16.67). Sputum culture conversion was not included 
as a variable in Table 3 because it is an intermediate in 
the causal pathway. Among all XDR TB patients, none of 
the included variables were associated with death (Table 3) 
or unfavorable treatment outcome as a composite outcome 
of death, treatment failure, and default. Among the subset 
of HIV co-infected XDR TB patients (Table 4), ART was 
protective against death by multivariate analysis (HR 0.46, 
95% CI 0.22–0.94). When further stratified by CD 4 T-cell 
count/mm3, HIV co-infected XDR TB patients with CD4 
cell counts >200/mm3 who received ART had substantially 
lower risk for death than patients with CD4 cell counts 
<200/mm3 who were not receiving ART (HR 0.094, 95% 
CI 0.007–1.22), but this result was not significant.
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Although ART was protective against death among 
patients co-infected with XDR TB and HIV, it was not 
associated with sputum culture conversion. After we 
adjusted for age, sex, ART use, previous TB treatment, 
adverse drug reactions, and a baseline CD4 cell count 
<200/mm3 by using the Cox proportional hazards model, 
we found that ART use was not associated with culture 
conversion after 2 months of treatment (HR 0.90, 95% CI 
0.23–3.51) or culture conversion during treatment (HR 
1.13, 95% CI 0.47–2.7).
When we compared data for HIV co-infected patients 
hospitalized for initiation of treatment from the first period 
of the study (December 2006–May 2007) with data of 
patients hospitalized during the second period (May 2007–
November 2007), we found a significant trend toward a 
higher percentage receiving ART (21/43, 49% vs. 29/39, 
74%, respectively; p = 0.02). Multivariate analysis showed 
that HIV-negative women had higher survival rates 
than HIV-negative men (HR 0.08, 95% CI 0.01–0.61), 
Conversely, HIV-positive women had lower survival rates 
than HIV-positive men (HR 1.82, 95% CI 0.83–4.01), but 
the difference was not significant.
Data for 109 (96%) patients were analyzed from time 
of diagnosis. Date of XDR TB diagnosis was unknown for 
5 patients. Median time between diagnosis and initiation 
of therapy was 101 days (IQR 68–150 days). For patients 
who died, median time between diagnosis and initiation of 
therapy was 83.5 days (IQR 64–135 days). For patients who 
survived, median time between diagnosis and initiation of 
therapy was 118 days (IQR 75.5–163.5 days).
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Table 1. Demographic characteristics of patients with XDR TB, KwaZulu-Natal Province, South Africa* 
Characteristic All patients, n = 114 Female patients, n = 65 Male patients, n = 49 p value 
Sex     
 M 49 (43.0) NA NA NA 
 F 65 (57.0) NA NA NA 
Age, y     
 18–25 16 (14.0) 16 (24.6) 0 <0.0001 
 26–35 42 (36.8) 27 (41.5) 15 (30.6) <0.0001 
 36–50 46 (40.4) 21 (32.3) 25 (51.0) NA 
 >50 10 (8.8) 1 (1.5) 9 (18.4) MA 
 Median age (IQR) 35 (30–42) 31 (26–37) 39 (35–47) NA 
HIV status     
 Positive 82 (71.9) 52 (80.0) 30 (61.2) 0.0153 
 Negative 25 (21.9) 8 (12.3) 17 (34.7) NA 
 Unknown 7 (6.1) 5 (7.7) 2 (4.1) NA 
CD4 cell count/mm3†     
 Known 55 (67.1) 38 (73.1) 17 (56.7) 0.1487 
 Not determined 27 (32.9)  14 (26.9) 13 (43.3) 0.1426 
 Median (IQR) 197 (80–300) 222 (71–316) 130 (83–254) NA 
Receiving ART†     
 Yes 50 (61.0) 34 (65.4) 16 (53.3) 0.3492 
 No 32 (39.0) 18 (34.6) 14 (46.7) NA 
Severe adverse event‡     
 Yes 29 (25.4) 29 (25.4) 12 (24.5) 1.0000 
 No 85 (74.6) 48 (73.9) 37 (75.5) NA 
Previous TB treatment     
 Yes 92 (80.7) 53 (81.5) 39 (79.6) 0.7216 
 No 15 (13.2) 9 (13.9) 6 (12.2) NA 
 Unknown 7 (6.1) 3 (4.6) 4 (8.2) NA 
Previous MDR TB diagnosis     
 Yes 69 (60.5) 41 (63.1) 28 (57.1) 0.5649 
 No 45 (39.5) 24 (36.9) 21 (42.9) NA 
Health care worker     
 Yes 6 (5.3) 4 (6.2) 2 (4.1) 0.6982 
 No 108 (94.7) 61 (93.9) 47 (95.9) NA 
Type of TB     
 Pulmonary 103 (90.4) 58 (89.2) 45 (91.8) NA 
 Extrapulmonary 11 (9.7) 7 (10.8) 4 (8.2) NA 
Culture conversion, mo§     
 None 72 (63.2) 40 (61.5) 32 (65.3) 0.2523 
 <2 16 (14.0) 7 (10.8) 9 (18.4) NA 
 >2 26 (22.8) 18 (27.7) 8 (16.3) NA 
*Values are no. (%) unless otherwise indicated. XDR TB, extensively drug-resistant tuberculosis; NA, not applicable; IQR, interquartile range; ART, 
antiretroviral therapy; MDR TB, multidrug-resistant TB.  
†Among HIV-positive patients only.  
‡Resulted in changes in clinical status or electrolyte abnormalities or required change of TB treatment regimen. 
§After initiation of treatment. 
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Time to culture conversion appeared to be an insensitive 
predictor of successful 24-month treatment outcome 
because for culture conversion at 6 months, sensitivity 
was only 51% (positive predictive value 85%; negative 
predictive value 57%) (Table 5). Culture conversion was a 
better predictor of survival at 24 months because for culture 
conversion at 6 months, sensitivity was 92% (positive 
predictive value = 62% and negative predictive value = 
97%) (Table 6).
Discussion
The main findings of our study were a high mortality 
rate (42%) and a low rate of successful treatment outcomes 
(22%) for XDR TB patients after completion of 24 months 
of treatment in a setting with a high incidence of HIV. 
All deaths in this cohort occurred in the first 12 months 
after start of treatment. Predictors of deaths in this cohort 
included TB-specific (TB culture conversion) and HIV-
specific (ART use) factors. Consistent with findings in 
other studies of treatment of drug-resistant TB/HIV, HIV 
was not independently associated with death (12,13,20). 
Although HIV was not independently associated with 
death, use of ART among HIV-infected patients was 
associated with improved survival. Sex appeared to modify 
the association between death and HIV because female sex 
was associated with higher survival rates among HIV-
negative XDR TB patients but with higher death rates in 
women co-infected with HIV than in men co-infected with 
HIV. However, this finding was not significant in all strata. 
TB culture conversion was a useful predictor of survival 
and treatment outcome. However, it was not sufficiently 
sensitive in this cohort to be a surrogate for successful 
TB treatment outcome, given the number of patients who 
ultimately showed treatment failure (n = 7), defaulted (n = 
7), or died (n = 4) after TB culture conversion.
Recently, 3 large, randomized, control trials of patients 
with drug-susceptible TB and co-infected with HIV have 
been conducted that analyzed different starting points for 
ART (21–23). Results of these trials showed that ART 
started early during TB treatment was associated with 
improved survival and that most decreases in mortality 
rates were for patients with low CD4 T-cell counts. As 
ART use increases among patients co-infected with MDR 
TB and HIV in KwaZulu-Natal Province, survival among 
these patients will probably improve. Higher rates of TB 
culture conversion through more effective drug regimens, 
including second-generation fluoroquinolones, high-dose 
isoniazid, and clofazimine, may further improve survival 
among XDR TB patients (24). Complete drug susceptibility 
testing for all drugs used should be performed at baseline 
and for XDR TB patients who do not show TB culture 
conversion after treatment to identify baseline and 
emergent second-line drug resistance. Furthermore, given 
that many patients showed reversion to sputum cell cultures 
positive for TB after initial culture conversion, optimal 
duration of XDR TB treatment remains unclear, Thus, 
new regimens, including more potent antimycobacterial 
agents such as linezolid, TMC207, or new nitromidazoles, 
may further increase sputum culture conversion rates and 
survival (25,26).
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Table 2. Twenty-four month treatment outcomes for 114 patients 
with extensively drug-resistant tuberculosis, KwaZulu-Natal 
Province, South Africa* 
Treatment outcome No. (%) patients 
Favorable  
 Cure 15 (3.2) 
 Completed 10 (8.8) 
Unfavorable   
 Withdrew* 19 (16.7) 
 Failure 22 (19.3) 
 Died 48 (42.0) 
*One patient initially withdrew and subsequently died. 
 
Figure 1. Kaplan-Meier curves for A) 114 HIV-positive (dashed line) and HIV-negative (solid line) patients receiving treatment for extensively 
drug-resistant tuberculosis (XDR TB) (p = 0.4966), and B) 82 HIV-infected patients with XDR TB receiving (dashed line) and not receiving 
(solid line) antiretroviral therapy (p = 0.0330), KwaZulu-Natal Province, South Africa. p values were adjusted for sex, TB treatment history, 
and HIV status.
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Although 4 deaths presumed secondary to capreomycin-
associated electrolyte abnormalities occurred early in the 
study period (12), clinicians became more vigilant, tested 
serum electrolytes more often, and used empiric electrolyte 
supplementation. Overall, adverse effects were not 
associated with failure to show sputum culture conversion. 
Treatment adherence was an unmeasured variable that had 
a major causal role during treatment for XDR TB and HIV 
infection. Thus, determining operational methods to measure 
and improve adherence to ART and second-line and third-
line anti-TB drugs is critical for improving outcomes.
Co-infection with drug-resistant TB and HIV has 
emerged as a major syndemic in South Africa and 
elsewhere (26) and has been comprehensively reviewed 
(27), However, to our knowledge, there are only 2 published 
studies of early results of treatment for co-infection with 
XDR TB and HIV. One study, published by our group 
(12), reported low rates of culture conversion (20%) and 
high mortality rates (42%) after a median of 12 months of 
treatment for the first 60 consecutive XDR TB patients in 
the current cohort. The second study, published by Dheda 
et al. (13) from Western Cape Province, South Africa, 
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Figure 2. A) Kaplan-Meier curves for sputum culture conversion for HIV-positive (dashed line) and HIV-negative (solid line) patients with 
extensively drug-resistant tuberculosis (XDR TB) receiving treatment, KwaZulu-Natal Province, South Africa. Sputum culture conversion 
is defined as 2 consecutive monthly TB cultures with no growth after 6 weeks of incubation after initiation of treatment (p = 0.706). p value 
was adjusted for age, initial smear result, and HIV status. B) Kaplan-Meier curves for patients receiving treatment for XDR TB stratified 
by sputum culture conversion status (p<0.0001). Solid line indicates conversion >2 months after initiation of treatment, dashed line 
indicates conversion >2 months after initiation of treatment, and top line with small and large dashes indicates no conversion. p values 
were adjusted for sex, TB treatment history, and HIV status. There was no significant difference between patients who showed culture 
conversion <2 months and >2 months after initiation of treatment (p = 0.5182).
 
Table 3. Predictors of 49 deaths at 24 months of treatment for 114 HIV-positive and HIV-negative XDR TB patients, KwaZulu-Natal 
Province, South Africa* 




Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value 
Sex       
 F 27/65 (41.5) 0.88 (0.50–1.54) 0.6484  0.95 (0.51–1.77) 0.8611 
 M 22/49 (44.9) 1.0 (referent) NA  1.0 (referent) NA 
Age, y       
 <36 25/58 (43.1) 1.03 (0.59–1.80) 0.9285  NA NA 
 >36 24/56 (42.9) 1.0 (referent) NA  NA NA 
Previous TB treatment‡       
 Yes 38/92 (41.3) 1.47 (0.53–4.13) 0.4614  1.28 (0.45–3.65) 0.6391 
 No 4/15 (26.7) 1.0 (referent) NA  1.0 (referent) NA 
 Unknown 7/7 (100) NA NA  NA NA 
Initial sputum smear result       
 Positive 30/67 (44.8) 1.05 (0.59–1.86) 0.8704  NA NA 
 Negative 19/47 (40.4) 1.0 (referent) NA  NA NA 
HIV status‡       
 Positive 36/82 (43.9) 1.14 (0.58–2.25) 0.6971  1.30 (0.61–2.78) 0.4966 
 Negative 11/25 (44.0) 1.0 (referent) NA  1.0 (referent)  
 Unknown 2/7 (28.6) NA NA  NA NA 
Adverse event       
 Yes 23/52 (44.2) 1.02 (0.58–1.79) 0.9420  NA NA 
 No 26/62 (41.9) 1.0 (referent) NA  NA NA 
*XDR TB, extensively drug-resistant tuberculosis; NA, not applicable. 
†Significant variables or variables that caused >10% change in the bivariate hazard ratio were included in the multivariate model. 
‡Patients whose HIV status or previous TB treatment history was unknown were excluded from analyses. 
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reported increased mortality rates (36%) and low culture 
conversion rates (19%) in 174 XDR TB patients after a 
median follow-up period of 6.9 months after the start of 
treatment for co-infection with XDR TB and HIV. This 
cohort had lower but substantial rates of co-infection with 
XDR TB and HIV and similarly showed no association 
between HIV and mortality rates for XDR TB patients 
receiving treatment but a protective effect for ART. There 
have been several cohort studies of XDR TB in settings 
with low incidence of HIV, including South Korea, Europe, 
Peru, and the United States (28–33). Successful treatment 
outcomes at 24 months of treatment ranged from 28% to 
60%. Only 2 cohorts from Lithuania (32) and the United 
States (34) included patients co-infected with HIV.
Limitations to our study included survival bias 
associated with an observational study at a TB referral 
hospital. Median time from diagnosis to initiation of 
treatment for XDR TB was 101 days, which did not 
decrease over the time of the study. A total of 50%–70% 
of patients with a diagnosis of MDR TB in KwaZulu-
Natal Province had not initiated treatment (11,35), and 
those who survived to study referral are probably unique 
because they were less immunocompromised and had a 
higher rate of treatment (11). We found no association 
between HIV status and survival or treatment outcome. 
This result probably reflects countervailing outcomes of 
patients who received ART and those who did not receive 
ART. However, this lack of association might be caused 
by misclassification (refusal to participate in HIV testing), 
or survival bias.
Because data were collected retrospectively, there 
were missing data for ART adherence, repeat CD4 T-cell 
counts, HIV RNA virus loads, adverse events, and details 
on ART started subsequent to inpatient hospitalization 
for XDR TB treatment initiation, which may have led 
to misclassification bias. This result would presumably 
bias HIV-associated variables toward the null hypothesis. 
The study was also limited by lack of full TB drug 
susceptibility testing for capreomycin, PAS, cycloserine, 
or terizadone to guide treatment choices. Most concerning 
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Table 4. Predictors of 36 deaths at 24 months of treatment for 82 HIV-positive XDR TB patients, KwaZulu-Natal Province, South 
Africa* 




Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value 
Sex       
 F 26/52 (50.0) 1.55 (0.75–3.21) 0.2405  1.82 (0.83–4.01) 0.1349 
 M 10/30 (33.3) 1.0 (referent) NA  1.0 (referent) NA 
Age, y       
 <36 20/45 (44.4) 1.05 (0.55–2.03) 0.8765  NA NA 
 >36 16/37 (43.2) 1.0 (referent) NA  NA NA 
Previous TB treatment‡       
 Yes 29/66 (43.9) 1.68 (0.51–5.52) 0.3913  1.70 (0.51–5.65) 0.3865 
 No 3/12 (25.0) 1.0 (referent) NA  1.0 (referent) NA 
 Unknown 4/4 (100.0) NA NA  NA NA 
Initial sputum smear result       
 Positive 22/48 (45.8) 1.03 (0.53–2.01) 0.9354  NA NA 
 Negative 14/34 (41.2) 1.0 (referent) NA  NA NA 
Initial CD4 cell count/mm3       
 <200 13/29 (44.8) 1.02 (0.52–2.02) 0.9495  NA NA 
 >200 23/53 (43.4) 1.0 (referent) NA  NA NA 
Receiving ART       
 Yes 18/50 (36.0) 0.54 (0.28–1.03) 0.0633  0.46 (0.22–0.94) 0.0333 
 No 18/32 (56.3) 1.0 (referent) NA  1.0 (referent) NA 
Adverse event       
 Yes 18/35 (51.4) 1.43 (0.74–2.76) 0.2832  1.89 (0.92–3.86) 0.0812 
 No 18/47 (38.3) 1.0 (referent) NA  1.0 (referent) NA 
*XDR TB, extensively drug-resistant tuberculosis; NA, not applicable; ART, antiretroviral therapy. 
†Significant variables or variables that caused >10% change in the bivariate hazard ratio were included in the multivariate model. 
‡Patients whose previous TB treatment history was unknown were excluded from analyses. 
 
 
Table 5. Sputum culture conversion at intervals of successful treatment for XDR TB patients, KwaZulu-Natal Province, South Africa* 
Time from start 
of treatment, mo 
No. cultures 
converted/total (%) 
No. cultures converted/ 







1 4/114 (4) 4/42 (10) 5 98 75 43 
2 18/114 (16) 18/42 (43) 19 92 78 42 
3 29/114 (25) 29/42 (69) 35 88 79 51 
4 33/114 (29) 33/42 (79) 42 88 82 53 
6 39/114 (34) 39/42 (93) 51 88 85 57 
24 42/114 (37) NA NA NA NA NA 
*XDR TB, extensively drug-resistant tuberculosis; NA, not applicable. 
 
 
Treatment Outcomes for XDR TB and HIV Co-infection
was the lack of drug-resistance data for capreomycin. 
In a study published subsequent to our study period, 17 
of 19 M. tuberculosis isolates from the site of a well-
described TB outbreak in KwaZulu-Natal Province were 
capreomycin resistant (36). Because drug susceptibility 
testing for capreomycin was not available, we may not 
have identified all cases of XDR TB. Conversely, complete 
drug susceptibility testing would not have necessarily led 
to improved regimens because the availability of second-
line and third-line anti-TB drugs was limited during this 
period. In addition, second-generation fluoroquinolones, 
which may improve outcomes in XDR TB patients, were 
not available in the public sector for TB treatment during 
the study (37,38).
Although not addressed by our study, improvements 
in treatment outcomes for patients co-infected with MDR 
TB and HIV will require changes in HIV- and TB-related 
factors. For HIV, these include more rapid HIV testing 
for early initiation of ART, appropriate monitoring of 
CD4 T-cell counts, HIV virus load testing, appropriate 
opportunistic infection prophylaxis, and improvement 
in ART adherence. Although not addressed by our 
study, we recommend that for TB these improvements 
include widespread implementation of rapid diagnostics, 
particularly for smear-negative disease; early drug 
susceptibility testing for first-line and second line agents; 
improvement in adherence for second-line TB drugs; 
development of more effective anti-TB drugs and regimens; 
and guidance of drug selection by timely and ongoing drug 
susceptibility testing.
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